Skip to main content
Top
Published in: Current Hepatology Reports 4/2018

01-12-2018 | Hepatic Cancer (A Singal and A Mufti, Section Editors)

LI-RADS v2018: a Primer and Update for Clinicians

Authors: Kathryn J. Fowler, Elizabeth Hecht, Ania Z. Kielar, Amit G. Singal, Claude B. Sirlin

Published in: Current Hepatology Reports | Issue 4/2018

Login to get access

Abstract

Purpose of Review

To familiarize readers with recent updates and additions to the Liver Imaging and Reporting Data System (LI-RADS) v2018 for hepatocellular carcinoma surveillance, diagnosis, and treatment response assessment.

Recent Findings

US surveillance, diagnosis, and treatment response assessment algorithms are now incorporated into LI-RADS v2018. Updates to the diagnostic algorithm for CT and MRI include clarification of the LI-RADS appropriate population, revision of LR-5 criteria to match with those advocated by the American Association for Study of Liver Disease, new specific criteria for the LR-M category, and modification of the tumor in vein (TIV) category.

Summary

LI-RADS v2018 facilitates clear communication between radiologists and the rest of the health care team by standardizing imaging terminology, interpretation, and reporting. LI-RADS also enhances imaging quality by providing minimal technical requirements for hepatocellular carcinoma imaging. Recent updates address US surveillance, clarify terminology, and incorporate treatment response. With these updates, LI-RADS addresses the entire spectrum of hepatocellular carcinoma imaging from screening to treatment response, thereby further promoting its integration into practice.
Literature
1.
go back to reference Elsayes KM, Kielar AZ, Agrons MM, Szklaruk J, Tang A, Bashir MR, et al. Liver imaging reporting and data system: an expert consensus statement. J Hepatocell Carcinoma. 2017;4:29–39.CrossRef Elsayes KM, Kielar AZ, Agrons MM, Szklaruk J, Tang A, Bashir MR, et al. Liver imaging reporting and data system: an expert consensus statement. J Hepatocell Carcinoma. 2017;4:29–39.CrossRef
2.
go back to reference Radiology, A.C.O Liver imaging reporting and data systems (LI-RADS) v 2018 core. 2017 12–2017 [cited 2018 01–29-18]; Available from: (https://www.acr.org/Clinical-Resources/Reporting-and-Data-Systems/LI-RADS/CT-MRI-LI-RADS-v2018). Radiology, A.C.O Liver imaging reporting and data systems (LI-RADS) v 2018 core. 2017 12–2017 [cited 2018 01–29-18]; Available from: (https://​www.​acr.​org/​Clinical-Resources/​Reporting-and-Data-Systems/​LI-RADS/​CT-MRI-LI-RADS-v2018).
3.
go back to reference Aube C, et al. EASL and AASLD recommendations for the diagnosis of HCC to the test of daily practice. Liver Int. 2017;37(10):1515–25.CrossRef Aube C, et al. EASL and AASLD recommendations for the diagnosis of HCC to the test of daily practice. Liver Int. 2017;37(10):1515–25.CrossRef
4.
go back to reference Wald C, Russo MW, Heimbach JK, Hussain HK, Pomfret EA, Bruix J. New OPTN/UNOS policy for liver transplant allocation: standardization of liver imaging, diagnosis, classification, and reporting of hepatocellular carcinoma. Radiology. 2013;266(2):376–82.CrossRef Wald C, Russo MW, Heimbach JK, Hussain HK, Pomfret EA, Bruix J. New OPTN/UNOS policy for liver transplant allocation: standardization of liver imaging, diagnosis, classification, and reporting of hepatocellular carcinoma. Radiology. 2013;266(2):376–82.CrossRef
5.
go back to reference Heimbach JK. Overview of the updated AASLD guidelines for the management of HCC. Gastroenterol Hepatol (N Y). 2017;13(12):751–3. Heimbach JK. Overview of the updated AASLD guidelines for the management of HCC. Gastroenterol Hepatol (N Y). 2017;13(12):751–3.
6.
go back to reference Benson AB 3rd. Hepatobiliary cancer. Clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2003;1(1):94–108.CrossRef Benson AB 3rd. Hepatobiliary cancer. Clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2003;1(1):94–108.CrossRef
7.
go back to reference Tang A, Hallouch O, Chernyak V, Kamaya A, Sirlin CB. Epidemiology of hepatocellular carcinoma: target population for surveillance and diagnosis. Abdom Radiol (NY). 2018;43(1):13–25.CrossRef Tang A, Hallouch O, Chernyak V, Kamaya A, Sirlin CB. Epidemiology of hepatocellular carcinoma: target population for surveillance and diagnosis. Abdom Radiol (NY). 2018;43(1):13–25.CrossRef
8.
go back to reference Morgan TA, et al. US LI-RADS: ultrasound liver imaging reporting and data system for screening and surveillance of hepatocellular carcinoma. Abdom Radiol (NY). 2018;43(1):41–55.CrossRef Morgan TA, et al. US LI-RADS: ultrasound liver imaging reporting and data system for screening and surveillance of hepatocellular carcinoma. Abdom Radiol (NY). 2018;43(1):41–55.CrossRef
9.
go back to reference Simmons O, Fetzer DT, Yokoo T, Marrero JA, Yopp A, Kono Y, et al. Predictors of adequate ultrasound quality for hepatocellular carcinoma surveillance in patients with cirrhosis. Aliment Pharmacol Ther. 2017;45(1):169–77.CrossRef Simmons O, Fetzer DT, Yokoo T, Marrero JA, Yopp A, Kono Y, et al. Predictors of adequate ultrasound quality for hepatocellular carcinoma surveillance in patients with cirrhosis. Aliment Pharmacol Ther. 2017;45(1):169–77.CrossRef
10.
go back to reference Singal A, et al. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther. 2009;30(1):37–47.CrossRef Singal A, et al. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther. 2009;30(1):37–47.CrossRef
11.
go back to reference Tzartzeva K, et al. Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis. Gastroenterology. 2018;154(6):1706–18 e1.CrossRef Tzartzeva K, et al. Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis. Gastroenterology. 2018;154(6):1706–18 e1.CrossRef
12.
go back to reference Marks RM, Ryan A, Heba ER, Tang A, Wolfson TJ, Gamst AC, et al. Diagnostic per-patient accuracy of an abbreviated hepatobiliary phase gadoxetic acid-enhanced MRI for hepatocellular carcinoma surveillance. AJR Am J Roentgenol. 2015;204(3):527–35.CrossRef Marks RM, Ryan A, Heba ER, Tang A, Wolfson TJ, Gamst AC, et al. Diagnostic per-patient accuracy of an abbreviated hepatobiliary phase gadoxetic acid-enhanced MRI for hepatocellular carcinoma surveillance. AJR Am J Roentgenol. 2015;204(3):527–35.CrossRef
13.
go back to reference Besa C, Lewis S, Pandharipande PV, Chhatwal J, Kamath A, Cooper N, et al. Hepatocellular carcinoma detection: diagnostic performance of a simulated abbreviated MRI protocol combining diffusion-weighted and T1-weighted imaging at the delayed phase post gadoxetic acid. Abdom Radiol (NY). 2017;42(1):179–90.CrossRef Besa C, Lewis S, Pandharipande PV, Chhatwal J, Kamath A, Cooper N, et al. Hepatocellular carcinoma detection: diagnostic performance of a simulated abbreviated MRI protocol combining diffusion-weighted and T1-weighted imaging at the delayed phase post gadoxetic acid. Abdom Radiol (NY). 2017;42(1):179–90.CrossRef
14.
go back to reference Goossens N, Singal AG, King LY, Andersson KL, Fuchs BC, Besa C, et al. Cost-effectiveness of risk score-stratified hepatocellular carcinoma screening in patients with cirrhosis. Clin Transl Gastroenterol. 2017;8(6):e101.CrossRef Goossens N, Singal AG, King LY, Andersson KL, Fuchs BC, Besa C, et al. Cost-effectiveness of risk score-stratified hepatocellular carcinoma screening in patients with cirrhosis. Clin Transl Gastroenterol. 2017;8(6):e101.CrossRef
15.
go back to reference • Fraum TJ, et al. Differentiation of hepatocellular carcinoma from other hepatic malignancies in patients at risk: diagnostic performance of the liver imaging reporting and data system version 2014. Radiology. 2018;286(1):158–72 Single-center retrospective study with pathological reference standard, evaluated the features of non-HCC malignancies in an at risk cohort to help define LR-M and TIV criteria for v2017. CrossRef • Fraum TJ, et al. Differentiation of hepatocellular carcinoma from other hepatic malignancies in patients at risk: diagnostic performance of the liver imaging reporting and data system version 2014. Radiology. 2018;286(1):158–72 Single-center retrospective study with pathological reference standard, evaluated the features of non-HCC malignancies in an at risk cohort to help define LR-M and TIV criteria for v2017. CrossRef
16.
go back to reference Fowler KJ, Potretzke TA, Hope TA, Costa EA, Wilson SR. LI-RADS M (LR-M): definite or probable malignancy, not specific for hepatocellular carcinoma. Abdom Radiol (NY). 2018;43(1):149–57.CrossRef Fowler KJ, Potretzke TA, Hope TA, Costa EA, Wilson SR. LI-RADS M (LR-M): definite or probable malignancy, not specific for hepatocellular carcinoma. Abdom Radiol (NY). 2018;43(1):149–57.CrossRef
17.
go back to reference Santillan C, Chernyak V, Sirlin C. LI-RADS categories: concepts, definitions, and criteria. Abdom Radiol (NY). 2018;43(1):101–10.CrossRef Santillan C, Chernyak V, Sirlin C. LI-RADS categories: concepts, definitions, and criteria. Abdom Radiol (NY). 2018;43(1):101–10.CrossRef
18.
go back to reference Santillan C, Fowler K, Kono Y, Chernyak V. LI-RADS major features: CT, MRI with extracellular agents, and MRI with hepatobiliary agents. Abdom Radiol (NY). 2018;43(1):75–81.CrossRef Santillan C, Fowler K, Kono Y, Chernyak V. LI-RADS major features: CT, MRI with extracellular agents, and MRI with hepatobiliary agents. Abdom Radiol (NY). 2018;43(1):75–81.CrossRef
19.
go back to reference Chernyak V, Santillan CS, Papadatos D, Sirlin CB. LI-RADS((R)) algorithm: CT and MRI. Abdom Radiol (NY). 2018;43(1):111–26.CrossRef Chernyak V, Santillan CS, Papadatos D, Sirlin CB. LI-RADS((R)) algorithm: CT and MRI. Abdom Radiol (NY). 2018;43(1):111–26.CrossRef
20.
go back to reference Chernyak V, Tang A, Flusberg M, Papadatos D, Bijan B, Kono Y, et al. LI-RADS((R)) ancillary features on CT and MRI. Abdom Radiol (NY). 2018;43(1):82–100.CrossRef Chernyak V, Tang A, Flusberg M, Papadatos D, Bijan B, Kono Y, et al. LI-RADS((R)) ancillary features on CT and MRI. Abdom Radiol (NY). 2018;43(1):82–100.CrossRef
21.
go back to reference CORE, A.L.R. 2017; Available from: chrome-extension://oemmndcbldboiebfnladdacbdfmadadm/https://www.acr.org/-/media/ACR/Files/RADS/LI-RADS/LIRADS_2017_Core.pdf?la=en. CORE, A.L.R. 2017; Available from: chrome-extension://oemmndcbldboiebfnladdacbdfmadadm/https://​www.​acr.​org/​-/​media/​ACR/​Files/​RADS/​LI-RADS/​LIRADS_​2017_​Core.​pdf?​la=​en.​
22.
go back to reference •• Tang A, et al. Evidence supporting LI-RADS major features for CT- and MR imaging-based diagnosis of hepatocellular carcinoma: a systematic review. Radiology. 2018;286(1):29–48 Systematic review that captures current evidence supporting LI-RADS major features and categories. CrossRef •• Tang A, et al. Evidence supporting LI-RADS major features for CT- and MR imaging-based diagnosis of hepatocellular carcinoma: a systematic review. Radiology. 2018;286(1):29–48 Systematic review that captures current evidence supporting LI-RADS major features and categories. CrossRef
23.
go back to reference Zhang YD, Zhu FP, Xu X, Wang Q, Wu CJ, Liu XS, et al. Liver imaging reporting and data system: substantial discordance between CT and MR for imaging classification of hepatic nodules. Acad Radiol. 2016;23(3):344–52.CrossRef Zhang YD, Zhu FP, Xu X, Wang Q, Wu CJ, Liu XS, et al. Liver imaging reporting and data system: substantial discordance between CT and MR for imaging classification of hepatic nodules. Acad Radiol. 2016;23(3):344–52.CrossRef
24.
go back to reference Fowler KJ, Tang A, Santillan C, Bhargavan-Chatfield M, Heiken J, Jha RC, et al. Interreader reliability of LI-RADS version 2014 algorithm and imaging features for diagnosis of hepatocellular carcinoma: a large international multireader study. Radiology. 2018;286(1):173–85.CrossRef Fowler KJ, Tang A, Santillan C, Bhargavan-Chatfield M, Heiken J, Jha RC, et al. Interreader reliability of LI-RADS version 2014 algorithm and imaging features for diagnosis of hepatocellular carcinoma: a large international multireader study. Radiology. 2018;286(1):173–85.CrossRef
25.
go back to reference Davenport MS, Khalatbari S, Liu PSC, Maturen KE, Kaza RK, Wasnik AP, et al. Repeatability of diagnostic features and scoring systems for hepatocellular carcinoma by using MR imaging. Radiology. 2014;272(1):132–42.CrossRef Davenport MS, Khalatbari S, Liu PSC, Maturen KE, Kaza RK, Wasnik AP, et al. Repeatability of diagnostic features and scoring systems for hepatocellular carcinoma by using MR imaging. Radiology. 2014;272(1):132–42.CrossRef
26.
go back to reference Becker AS, Barth BK, Marquez PH, Donati OF, Ulbrich EJ, Karlo C, et al. Increased interreader agreement in diagnosis of hepatocellular carcinoma using an adapted LI-RADS algorithm. Eur J Radiol. 2017;86:33–40.CrossRef Becker AS, Barth BK, Marquez PH, Donati OF, Ulbrich EJ, Karlo C, et al. Increased interreader agreement in diagnosis of hepatocellular carcinoma using an adapted LI-RADS algorithm. Eur J Radiol. 2017;86:33–40.CrossRef
27.
go back to reference Ehman EC, Behr SC, Umetsu SE, Fidelman N, Yeh BM, Ferrell LD, et al. Rate of observation and inter-observer agreement for LI-RADS major features at CT and MRI in 184 pathology proven hepatocellular carcinomas. Abdom Radiol (NY). 2016;41(5):963–9.CrossRef Ehman EC, Behr SC, Umetsu SE, Fidelman N, Yeh BM, Ferrell LD, et al. Rate of observation and inter-observer agreement for LI-RADS major features at CT and MRI in 184 pathology proven hepatocellular carcinomas. Abdom Radiol (NY). 2016;41(5):963–9.CrossRef
28.
go back to reference Sofue K, Sirlin CB, Allen BC, Nelson RC, Berg CL, Bashir MR. How reader perception of capsule affects interpretation of washout in hypervascular liver nodules in patients at risk for hepatocellular carcinoma. J Magn Reson Imaging. 2016;43(6):1337–45.CrossRef Sofue K, Sirlin CB, Allen BC, Nelson RC, Berg CL, Bashir MR. How reader perception of capsule affects interpretation of washout in hypervascular liver nodules in patients at risk for hepatocellular carcinoma. J Magn Reson Imaging. 2016;43(6):1337–45.CrossRef
29.
go back to reference Bashir MR, Huang R, Mayes N, Marin D, Berg CL, Nelson RC, et al. Concordance of hypervascular liver nodule characterization between the organ procurement and transplant network and liver imaging reporting and data system classifications. J Magn Reson Imaging. 2015;42(2):305–14.CrossRef Bashir MR, Huang R, Mayes N, Marin D, Berg CL, Nelson RC, et al. Concordance of hypervascular liver nodule characterization between the organ procurement and transplant network and liver imaging reporting and data system classifications. J Magn Reson Imaging. 2015;42(2):305–14.CrossRef
30.
go back to reference Choi, M.H., Park G.E., Oh S.N., Park M.Y., Rha S.E., Lee Y.J., Jung S.E., Choi J.I., Reproducibility of mRECIST in measurement and response assessment for hepatocellular carcinoma treated by transarterial chemoembolization. Acad Radiol, 2018. Choi, M.H., Park G.E., Oh S.N., Park M.Y., Rha S.E., Lee Y.J., Jung S.E., Choi J.I., Reproducibility of mRECIST in measurement and response assessment for hepatocellular carcinoma treated by transarterial chemoembolization. Acad Radiol, 2018.
31.
go back to reference Lencioni R, Montal R, Torres F, Park JW, Decaens T, Raoul JL, et al. Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC. J Hepatol. 2017;66(6):1166–72.CrossRef Lencioni R, Montal R, Torres F, Park JW, Decaens T, Raoul JL, et al. Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC. J Hepatol. 2017;66(6):1166–72.CrossRef
32.
go back to reference • Ronot M, et al. Comparison of the accuracy of AASLD and LI-RADS criteria for the non-invasive diagnosis of HCC smaller than 3cm. J Hepatol. 2017; Prospective study comparing diagnostic accuracy of AASLD and LI-RADS in at-risk cohort, helps establish high PPV/specificity for LR-5 criteria. • Ronot M, et al. Comparison of the accuracy of AASLD and LI-RADS criteria for the non-invasive diagnosis of HCC smaller than 3cm. J Hepatol. 2017; Prospective study comparing diagnostic accuracy of AASLD and LI-RADS in at-risk cohort, helps establish high PPV/specificity for LR-5 criteria.
33.
go back to reference Kim YY, An C, Kim S, Kim MJ. Diagnostic accuracy of prospective application of the liver imaging reporting and data system (LI-RADS) in gadoxetate-enhanced MRI. Eur Radiol. 2018;28(5):2038–46.CrossRef Kim YY, An C, Kim S, Kim MJ. Diagnostic accuracy of prospective application of the liver imaging reporting and data system (LI-RADS) in gadoxetate-enhanced MRI. Eur Radiol. 2018;28(5):2038–46.CrossRef
34.
go back to reference Choi SH, et al. Liver imaging reporting and data system v2014 with gadoxetate disodium-enhanced magnetic resonance imaging: validation of LI-RADS category 4 and 5 criteria. Investig Radiol. 2016;51(8):483–90.CrossRef Choi SH, et al. Liver imaging reporting and data system v2014 with gadoxetate disodium-enhanced magnetic resonance imaging: validation of LI-RADS category 4 and 5 criteria. Investig Radiol. 2016;51(8):483–90.CrossRef
35.
go back to reference Darnell A, Forner A, Rimola J, Reig M, García-Criado Á, Ayuso C, et al. Liver imaging reporting and data system with MR imaging: evaluation in nodules 20 mm or smaller detected in cirrhosis at screening US. Radiology. 2015;275(3):698–707.CrossRef Darnell A, Forner A, Rimola J, Reig M, García-Criado Á, Ayuso C, et al. Liver imaging reporting and data system with MR imaging: evaluation in nodules 20 mm or smaller detected in cirrhosis at screening US. Radiology. 2015;275(3):698–707.CrossRef
36.
go back to reference Cerny M, et al. LI-RADS for MR imaging diagnosis of hepatocellular carcinoma: performance of major and ancillary features. Radiology. 2018:171678. Cerny M, et al. LI-RADS for MR imaging diagnosis of hepatocellular carcinoma: performance of major and ancillary features. Radiology. 2018:171678.
37.
go back to reference Tanabe M, et al. Imaging outcomes of liver imaging reporting and data system version 2014 category 2, 3, and 4 observations detected at CT and MR imaging. Radiology. 2016;281(1):129–39.CrossRef Tanabe M, et al. Imaging outcomes of liver imaging reporting and data system version 2014 category 2, 3, and 4 observations detected at CT and MR imaging. Radiology. 2016;281(1):129–39.CrossRef
38.
go back to reference Choi JY, Cho HC, Sun M, Kim HC, Sirlin CB. Indeterminate observations (liver imaging reporting and data system category 3) on MRI in the cirrhotic liver: fate and clinical implications. AJR Am J Roentgenol. 2013;201(5):993–1001.CrossRef Choi JY, Cho HC, Sun M, Kim HC, Sirlin CB. Indeterminate observations (liver imaging reporting and data system category 3) on MRI in the cirrhotic liver: fate and clinical implications. AJR Am J Roentgenol. 2013;201(5):993–1001.CrossRef
39.
go back to reference Burke LM, et al. Natural history of liver imaging reporting and data system category 4 nodules in MRI. Abdom Radiol (NY). 2016;41(9):1758–66.CrossRef Burke LM, et al. Natural history of liver imaging reporting and data system category 4 nodules in MRI. Abdom Radiol (NY). 2016;41(9):1758–66.CrossRef
40.
go back to reference An C, Park S, Chung YE, Kim DY, Kim SS, Kim MJ, et al. Curative resection of single primary hepatic malignancy: liver imaging reporting and data system category LR-M portends a worse prognosis. AJR Am J Roentgenol. 2017;209(3):576–83.CrossRef An C, Park S, Chung YE, Kim DY, Kim SS, Kim MJ, et al. Curative resection of single primary hepatic malignancy: liver imaging reporting and data system category LR-M portends a worse prognosis. AJR Am J Roentgenol. 2017;209(3):576–83.CrossRef
41.
go back to reference Joo I, Lee JM, Lee SM, Lee JS, Park JY, Han JK. Diagnostic accuracy of liver imaging reporting and data system (LI-RADS) v2014 for intrahepatic mass-forming cholangiocarcinomas in patients with chronic liver disease on gadoxetic acid-enhanced MRI. J Magn Reson Imaging. 2016;44(5):1330–8.CrossRef Joo I, Lee JM, Lee SM, Lee JS, Park JY, Han JK. Diagnostic accuracy of liver imaging reporting and data system (LI-RADS) v2014 for intrahepatic mass-forming cholangiocarcinomas in patients with chronic liver disease on gadoxetic acid-enhanced MRI. J Magn Reson Imaging. 2016;44(5):1330–8.CrossRef
Metadata
Title
LI-RADS v2018: a Primer and Update for Clinicians
Authors
Kathryn J. Fowler
Elizabeth Hecht
Ania Z. Kielar
Amit G. Singal
Claude B. Sirlin
Publication date
01-12-2018
Publisher
Springer US
Published in
Current Hepatology Reports / Issue 4/2018
Electronic ISSN: 2195-9595
DOI
https://doi.org/10.1007/s11901-018-0441-7

Other articles of this Issue 4/2018

Current Hepatology Reports 4/2018 Go to the issue

Hepatic Cancer (A Singal and A Mufti, Section Editors)

Stereotactic Ablative Radiotherapy (SABR/SBRT) for Hepatocellular Carcinoma

Portal Hypertension (J Gonzalez-Abraldes and E Tsochatzis, Section Editors)

Portal Cavernoma Cholangiopathy